San Diego, CA · Founded 2017 · Privately Held (backing)
Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy. Primmune Therapeutics is based in San Diego, CA and was founded in 2017. It was valued at $44 million at its early-stage round in Jan 2021, the last priced event on record. It has raised $63.2 million across 5 recorded rounds; the latest was a $13 million early-stage round in Oct 2020.
PMV mark · valuation
$44.0M
Oct 2026
Priced at
its early-stage round
Jan 2021
Total raised
$63.2M
Last round
Early Stage VC
Oct 2020
No prints on record
No secondary trades in Primmune Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Primmune Therapeutics with a free account
·Watch Primmune Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Primmune Therapeutics stock.
